CytoDyn Receives Institutional Review Board Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor Cancers Feb 21, 2020 6:00am EST
CytoDyn Interview to Air on Bloomberg International on the RedChip Money Report Feb 20, 2020 2:00pm EST
CytoDyn Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA Feb 14, 2020 6:00am EST
CytoDyn Signs Letter of Intent for the Joint Development and Licensing of Leronlimab in China with Longen China Group Feb 12, 2020 8:58am EST
CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on February 11, 2020 Feb 10, 2020 6:00am EST
CytoDyn Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers Feb 06, 2020 6:00am EST
CytoDyn Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition Jan 31, 2020 6:00am EST
CytoDyn Appoints Maura Fleming as Vice President, General Counsel and Corporate Secretary Jan 23, 2020 8:00am EST
